menu
    • menu
    [{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MicuRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MicuRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Beijing Chest Hospital, Capital Medical University | Jiangxi Provincial Chest Hospital | Bin Cao","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Beijing Chest Hospital, Capital Medical University | Jiangxi Provincial Chest Hospital | Bin Cao","highestDevelopmentStatusID":"11","companyTruncated":"MicuRx Pharmaceuticals \/ Beijing Chest Hospital, Capital Medical University | Jiangxi Provincial Chest Hospital | Bin Cao"},{"orgOrder":0,"company":"MicuRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MicuRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MicuRx \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Bin Cao | Shanghai Pulmonary Hospital | Beijing Chest Hospital | Anhui Chest Hospital | Jiangxi Chest Hospital | Guangzhou Chest Hospital.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial 70S ribosome","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Bin Cao | Shanghai Pulmonary Hospital | Beijing Chest Hospital | Anhui Chest Hospital | Jiangxi Chest Hospital | Guangzhou Chest Hospital.","highestDevelopmentStatusID":"11","companyTruncated":"MicuRx Pharmaceuticals \/ Bin Cao | Shanghai Pulmonary Hospital | Beijing Chest Hospital | Anhui Chest Hospital | Jiangxi Chest Hospital | Guangzhou Chest Hospital."}]

    Find Clinical Drug Pipeline Developments & Deals for Contezolid

    Menu

    Contezolid

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Sponsor : Bin Cao | Shanghai Pulmonary Hospital | Beijing Chest Hospital | Anhui Chest Hospital | Jiangxi Chest Hospital | Guangzhou Chest Hospital.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

                            Details : Contezolid is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Mycobacterium Avium Complex Pulmonary Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 09, 2025

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Bin Cao | Shanghai Pulmonary Hospital | Beijing Chest Hospital | Anhui Chest Hospital | Jiangxi Chest Hospital | Guangzhou Chest Hospital.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Sponsor : Beijing Chest Hospital, Capital Medical University | Jiangxi Provincial Chest Hospital | Bin Cao

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Short-term Bactericidal Effect of Contezolid in MAC-PD

                            Details : Contezolid is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Mycobacterium Avium Complex Pulmonary Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 24, 2025

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Beijing Chest Hospital, Capital Medical University | Jiangxi Provincial Chest Hospital | Bin Cao

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China

                            Details : MRX-4 (contezolid) is a novel oxazolidinone-class antibacterial drug. Currently, it is being investigated in the late-stage clinical trial studies for the treatment of cSSTI in China.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 29, 2024

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            MicuRx Pharmaceuticals

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection

                            Details : The approval of contezolid from NMPA is based on the efficacy and safety result obtained from a multi-center, randomized, double-blind, double-dummy Phase III clinical trial involving 719 patients with complicated skin and soft tissue infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 02, 2021

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MicuRx

                            Country arrow
                            ACI Convention
                            Not Confirmed

                            MicuRx

                            Country arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection

                            Details : MRX-I is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bacterial Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 21, 2014

                            Lead Product(s) : Contezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth